Evidence map›Paper›PMID 29120691›Full record

ArticlePediatric hematology and oncology

Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL): Overview and introduction to the proceedings of the 2016 TACL investigator meeting.

Alan S Wayne, Erika Shin-Kashiyama, Richard Sposto, Paul Gaynon

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pediatric hematology and oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Alan S Waynea Children's Hospital of Los Angeles, USC Norris Comprehensive Cancer Center, Department of Pediatrics, Medicine, and Preventive Medicine , Keck School of Medicine, University of Southern California , Los Angeles , California , USA.
Erika Shin-Kashiyamaa Children's Hospital of Los Angeles, USC Norris Comprehensive Cancer Center, Department of Pediatrics, Medicine, and Preventive Medicine , Keck School of Medicine, University of Southern California , Los Angeles , California , USA.
Richard Spostoa Children's Hospital of Los Angeles, USC Norris Comprehensive Cancer Center, Department of Pediatrics, Medicine, and Preventive Medicine , Keck School of Medicine, University of Southern California , Los Angeles , California , USA.
Paul Gaynona Children's Hospital of Los Angeles, USC Norris Comprehensive Cancer Center, Department of Pediatrics, Medicine, and Preventive Medicine , Keck School of Medicine, University of Southern California , Los Angeles , California , USA.
Children's Hospital of Los Angeles · USUniversity of Southern California · US

Funding

USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Fumito Ito · 1985 to 2026
$181.4M
NCI NIH HHS P30 CA014089
6 · The paper itself

Abstract

Despite great success in the development of curative therapies for pediatric hematologic malignancies, new approaches are needed to overcome resistance to treatment and to reduce associated side effects. The Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium is an early phase clinical trial group dedicated to developing innovative therapies for currently incurable pediatric leukemias and lymphomas ( https://tacl.chla.usc.edu/tacl/ ). In November of 2016, a TACL Investigator Meeting was held, the proceedings of which appear in this edition of Pediatric Hematology Oncology. This introductory article provides an overview of TACL and introduces the five-part proceedings.

Indexed as

AdolescentChildChild, PreschoolClinical Trials as TopicCongresses as TopicFemaleHumansInfantInfant, NewbornLeukemiaLymphomaMaleClinical trialsleukemialymphomamolecularly targeted agentspediatric

Identifiers

PMID29120691
PMCPMC6122960
OpenAlexW2767717114

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.